These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18442635)

  • 1. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice.
    Matsumoto M; Tanimoto M; Gohda T; Aoki T; Murakoshi M; Yamada K; Yamazaki T; Kaneko S; Horikoshi S; Tomino Y
    Metabolism; 2008 May; 57(5):691-7. PubMed ID: 18442635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
    Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
    Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
    Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin β4 attenuates early diabetic nephropathy in a mouse model of type 2 diabetes mellitus.
    Zhu J; Su LP; Zhou Y; Ye L; Lee KO; Ma JH
    Am J Ther; 2015; 22(2):141-6. PubMed ID: 23846524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.
    Mitsuhashi T; Uemoto R; Ishikawa K; Yoshida S; Ikeda Y; Yagi S; Matsumoto T; Akaike M; Aihara KI
    J Atheroscler Thromb; 2018 Jan; 25(1):65-80. PubMed ID: 28592707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
    Tanimoto M; Fan Q; Gohda T; Shike T; Makita Y; Tomino Y
    Metabolism; 2004 Nov; 53(11):1473-9. PubMed ID: 15536604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol.
    Mori Y; Hirano T
    Metabolism; 2012 Mar; 61(3):379-88. PubMed ID: 21868047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice.
    Aoki T; Kaneko S; Tanimoto M; Gohda T; Hagiwara S; Murakoshi M; Ishikawa Y; Furukawa M; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2012; 25(1):127-36. PubMed ID: 21725918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
    Yagi S; Aihara K; Ikeda Y; Sumitomo Y; Yoshida S; Ise T; Iwase T; Ishikawa K; Azuma H; Akaike M; Matsumoto T
    Circ Res; 2008 Jan; 102(1):68-76. PubMed ID: 17967781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells.
    Wang J; Tokoro T; Matsui K; Higa S; Kitajima I
    Life Sci; 2005 Mar; 76(19):2257-68. PubMed ID: 15733940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.
    Miyashita Y; Endo K; Saiki A; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):539-45. PubMed ID: 19907100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.
    Huang CH; Huang YY; Hsu BR
    J Diabetes Investig; 2016 Sep; 7(5):769-76. PubMed ID: 27181110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S
    Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production.
    Shinozaki K; Nishio Y; Ayajiki K; Yoshida Y; Masada M; Kashiwagi A; Okamura T
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):122-30. PubMed ID: 17414223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic bladder dysfunction in T2D KK-Ay mice and its changes in the level of relevant gene expression.
    Zhang J; Zhang Y; Yang X; Wang J; Xu Y; Wang R; Tan B; Huang P; Cao H
    Biomed Pharmacother; 2020 Nov; 131():110706. PubMed ID: 33152907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.